Form 4: Septerna Director Alan Ezekowitz Granted 16,623 Stock Options

Septerna, Inc. Director Alan Ezekowitz was granted 16,623 stock options with an exercise price of $10.24, vesting upon the earlier of June 17, 2026, or the company's next annual meeting of stockholders.

Summary

• Alan Ezekowitz, a Director of Septerna, Inc. (SEPN), was granted 16,623 stock options.
• The transaction date for this grant was June 17, 2025.
• Each stock option has an exercise price of $10.24.
• The options will vest in full upon the earlier of June 17, 2026, or Septerna's next annual meeting of stockholders.
• Vesting is contingent upon Mr. Ezekowitz's continued service to the Issuer through the vesting date.
• The stock options have an expiration date of June 16, 2035.
• Following this transaction, Mr. Ezekowitz beneficially owns 16,623 derivative securities (stock options) directly.

Sentiment

Score: 6

Explanation: The sentiment is mildly positive as it represents a routine compensation event that aligns the director's interests with shareholders, without indicating any negative operational or financial news.

Positives

• The grant of stock options to a director aligns their financial interests with the long-term performance of the company and its shareholders.

Risks

• The document, being a Form 4, primarily reports an insider transaction and does not detail company-specific operational or financial risks. The value of the options is subject to the future stock price performance of Septerna, Inc.

Future Outlook

The stock options granted to Director Alan Ezekowitz are set to vest in full upon the earlier of June 17, 2026, or the Issuer's next annual meeting of stockholders, contingent on his continued service. This indicates a future milestone for the director's equity compensation.

Industry Context

The grant of stock options to directors is a standard practice in publicly traded companies, particularly in the biotechnology and pharmaceutical sectors, as a form of non-cash compensation. This practice is designed to incentivize long-term commitment and align the interests of the board members with the company's performance and shareholder value creation.

Comparison to Industry Standards

• The grant of stock options to a director is a common form of compensation in publicly traded companies, particularly in the biotechnology sector, aiming to align the director's long-term interests with those of shareholders.
• Specific comparisons to other companies' director compensation would require detailed analysis of their compensation policies, company stage, and market capitalization, which is beyond the scope of this Form 4 filing. However, the structure of a single-tranche, time-based vesting option grant is typical for director equity awards.

Related Party Transactions

• The grant of stock options to Alan Ezekowitz, a Director of Septerna, Inc., constitutes a related party transaction as it involves compensation provided by the company to an insider.

Stakeholder Impact

• Shareholders: The grant aligns the director's interests with shareholders, potentially incentivizing decisions that enhance long-term stock value.
• Director (Alan Ezekowitz): Receives equity compensation, which is a significant component of director remuneration, contingent on continued service and company performance.

Next Steps

• The stock options will vest upon the earlier of June 17, 2026, or Septerna's next annual meeting of stockholders, subject to continued service.
• Following vesting, the director may choose to exercise the options at the specified exercise price before the expiration date of June 16, 2035.

Key Dates

Keywords

Septerna, SEPN, stock option, director compensation, insider transaction, Form 4, equity grant, executive compensation